#Coronavirus Disease Research #References (AMEDEO, September 13 '26)

 

Eur J Radiol

1. GARCIA-HIDALGO C, Naval-Baudin P, Garcia-Garcia JI, Viveros-Castano M, et al
   Dynamic susceptibility contrast perfusion-weighted imaging (DSC-PWI) vascular and metabolic biomarkers for presurgical diagnosis of adult brain tumors across different acquisition parameters.
   Eur J Radiol. 2026;205:113218.
   PubMed         Abstract available
   
   

   
   J Infect

2. QIAN J, Zhang Z, Zhang L
   SARS?CoV?2 spike CTD suppresses host metabolism but restricts viral entry through a PDZ?dependent trade?off.
   J Infect. 2026 Sep 11:106857. doi: 10.1016/j.jinf.2026.106857.
   PubMed        
   
   
3. MAZARAKIS N, Toh ZQ, Neal E, Nguyen C, et al
   Corrigendum to 'Immunogenicity and efficacy over 12 months following a fourth dose of a bivalent mRNA or protein-based COVID-19 vaccine: A randomised controlled trial in Australia' [J Infect 92 (2026)/106727].
   J Infect. 2026;93:106851.
   PubMed        
   
   
4. MAZARAKIS N, Toh ZQ, Neal E, Bright K, et al
   Corrigendum to "The immunogenicity, reactogenicity, and safety of a bivalent mRNA or protein COVID-19 vaccine given as a fourth dose" [J Infect 90 (2025)/106447].
   J Infect. 2026;93:106850.
   PubMed        
   
   

   
   J Med Virol

5. TIKHONOVA IV, Dyukina AR, Grinevich AA, Tutukina MN, et al
   Immunological Properties of SARS-CoV-2 S and M Protein Fragments and Their Effects on Respiratory Burst in Human Neutrophils.
   J Med Virol. 2026;98:e71151.
   PubMed         Abstract available
   
   
6. SREELAKSHMI PR, Wagh P, Sarje P, Shinde T, et al
   Distinct Cytokine Signatures and Antibody Neutralization Capacity Differentiate Post-Acute Sequelae of COVID-19 From Recovered Individuals Despite Comparable T Cell Responses.
   J Med Virol. 2026;98:e71145.
   PubMed         Abstract available
   
   

   
   J Travel Med

7. VAN GENDEREN PJJ, van Sprang ENM
   Artificial Intelligence and Complementary Digital Health Technologies Across the Travel Medicine Continuum: A Narrative Review.
   J Travel Med. 2026 Sep 9:taag082. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Virol

8. KIRK J, Sives S, Rayment A, Tappin A, et al
   Spike protein derived from an apathogenic IBV strain confers attenuated phenotype to a nephropathogenic IBV strain.
   J Virol. 2026 Sep 10:e0110326. doi: 10.1128/jvi.01103.
   PubMed         Abstract available
   
   
9. LIU M, Duong MTH, Laocharoensuk T, Aryal B, et al
   Mutations in the macrodomain 1 of nsp3 attenuate PEDV virulence in vivo without impairing in vitro replication.
   J Virol. 2026 Sep 9:e0125126. doi: 10.1128/jvi.01251.
   PubMed         Abstract available
   
   
10. YU R, Zhang L, Zhou P, Zhang Z, et al
    Low-pH-induced conformational changes in the spike protein promote porcine deltacoronavirus infection by enhancing viral binding efficiency to the porcine aminopeptidase receptor.
    J Virol. 2026 Sep 9:e0116826. doi: 10.1128/jvi.01168.
    PubMed         Abstract available
    
    
11. ALVARADO RE, Chen J, Lokugamage KG, Zhou Y, et al
    Antagonism of stress granules is key to SARS-CoV-2 infection and pathogenesis.
    J Virol. 2026 Sep 8:e0099226. doi: 10.1128/jvi.00992.
    PubMed         Abstract available
    
    
12. YAO Z, Zhu Y, Liu N, Hu Y, et al
    The alpha-helix-facilitating amino acid sequence EAAAK dramatically increases the antiviral activity of SARS-CoV-2 fusion-inhibitory peptides via the endosome fusion pathway.
    J Virol. 2026 Sep 8:e0106726. doi: 10.1128/jvi.01067.
    PubMed         Abstract available
    
    

    
    Life Sci

13. HAN D, Beurel E
    The spike protein S1 of SARS-CoV-2 promotes Th17 cell-dependent stress-induced depressive-like behaviors in mice.
    Life Sci. 2026 Sep 8:124672. doi: 10.1016/j.lfs.2026.124672.
    PubMed         Abstract available
    
    

    
    N Engl J Med

14. HAYDEN FG, Sax PE
    Ensitrelvir for Covid-19 Postexposure Prophylaxis. Reply.
    N Engl J Med. 2026;395:1039.
    PubMed        
    
    
15. SUZUKI J, Imai H, Endo S
    Ensitrelvir for Covid-19 Postexposure Prophylaxis.
    N Engl J Med. 2026;395:1039.
    PubMed        
    
    

    
    Travel Med Infect Dis

16. TIMPERLEY EK, Swithenbank L, Beeching NJ, Tang E, et al
    General physicians still fail to take travel histories.
    Travel Med Infect Dis. 2026 Sep 9:103021. doi: 10.1016/j.tmaid.2026.103021.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, September 13 '26)

 

Antimicrob Agents Chemother

1. PENG Z, Yuan H, Huang J, Lin X, et al
   A novel ursodeoxycholic acid derivative exhibits broad-spectrum antiviral activity against influenza A virus and coronaviruses by multiphasic disruption of the viral life cycle.
   Antimicrob Agents Chemother. 2026 Sep 9:e0028426. doi: 10.1128/aac.00284.
   PubMed         Abstract available
   
   

   
   BMC Pediatr

2. BOZZOLA E, Piccotti E, D'Auria E, Trapani S, et al
   RESPIRIAMO - Italian hospital surveillance for lower respiratory tract infections: a multicenter retrospective cohort study of respiratory syncytial virus-associated hospitalizations in children under 2 years of age.
   BMC Pediatr. 2026;26:853.
   PubMed         Abstract available
   
   

   
   J Infect

3. ZHU X, Deng Y, Xiao G, Zhang J, et al
   Re-emergence of H10N3 Avian Influenza Viruses in China: Evolutionary Dynamics and Emerging Zoonotic Risk.
   J Infect. 2026 Sep 7:106848. doi: 10.1016/j.jinf.2026.106848.
   PubMed        
   
   

   
   J Virol Methods

4. EZEANYAEGBU CN, Toledo NP, Corkum CP, Nelder M, et al
   Evaluation of one-step amplicon-based targeted enrichment for SARS-CoV-2 whole-genome sequencing using the Midnight amplicon scheme.
   J Virol Methods. 2026;346:115448.
   PubMed         Abstract available
   
   
5. KAZEMIAN S, Pedroza S, Santana-Pereira ALR, Neasham PJ, et al
   An enhanced multisegment RT-PCR method for influenza A virus sequencing: Improved performance and reduced preparation time over traditional methods.
   J Virol Methods. 2026;347:115453.
   PubMed         Abstract available
   
   

   
   PLoS Comput Biol

6. QUILTY BJ, Chapman LAC, Munday JD, Wong KLM, et al
   Disentangling the drivers of heterogeneity in SARS-CoV-2 transmission from data on viral load and daily contact rates.
   PLoS Comput Biol. 2026;22:e1014715.
   PubMed         Abstract available
   
   
7. SONG P, de Vlas SJ, Emery T, Coffeng LE, et al
   Mapping spatial colleague connectivity patterns from individual-level registry data to inform regional pandemic interventions.
   PLoS Comput Biol. 2026;22:e1014721.
   PubMed         Abstract available
   
   
8. PANT B, Lalovic M, Kiss IZ, Santillana M, et al
   The paradox of neglecting changes in behavior: How standard epidemic models misestimate both transmissibility and final epidemic size.
   PLoS Comput Biol. 2026;22:e1014746.
   PubMed         Abstract available
   
   
9. YUAN Z, Zhang X, Lin G, Zou Q, et al
   AET5: A transcriptome-guided molecular generation framework with contrastive self-supervised learning.
   PLoS Comput Biol. 2026;22:e1014703.
   PubMed         Abstract available
   
   
10. BENHAMOU W, Howerton E, Park SW, Viboud C, et al
    Leveraging perturbations to infer the population dynamics of human rhinovirus and interaction of influenza A virus.
    PLoS Comput Biol. 2026;22:e1014784.
    PubMed         Abstract available
    
    

    
    PLoS Med

11. LENGLART L, Titomanlio L, Alberti I, Almeida L, et al
    Association between nirsevimab coverage and pediatric emergency department visits for bronchiolitis in 12 European countries: An interrupted time-series analysis.
    PLoS Med. 2026;23:e1005223.
    PubMed         Abstract available
    
    

    
    PLoS One

12. KWON K, Jang CY, Kim W, Son J, et al
    Kinetics of the PASC Index in Long COVID.
    PLoS One. 2026;21:e0357670.
    PubMed         Abstract available
    
    
13. BATTU S, Moore AR, Lebold K, Pacheco-Navarro A, et al
    Outcomes of immunocompromised and non-immunocompromised patients in the ICU diverge late in the pandemic.
    PLoS One. 2026;21:e0357181.
    PubMed         Abstract available
    
    
14. JI M, Dong H, Xu Y, Wang Y, et al
    Development of a multiplex real-time PCR assay with fluorescence probe-melting-curve analysis for one-tube detection of respiratory pathogens.
    PLoS One. 2026;21:e0357377.
    PubMed         Abstract available
    
    
15. GONG X, Liu L, Lu Y, Zhang G, et al
    Sleepless in America: A social sensing study of pandemic-era sleeplessness using nighttime social media data.
    PLoS One. 2026;21:e0356547.
    PubMed         Abstract available
    
    
16. BHATIA A, Elser J, Carrell SJ, Kronmiller B, et al
    Correlation assessment of SARS-CoV-2 variants and their subvariants present in clinical and wastewater samples in Oregon, USA (February 7, 2021 - February 26, 2022) using the Freyja bioinformatics approach.
    PLoS One. 2026;21:e0357591.
    PubMed         Abstract available
    
    
17. MOHD YUSOFF H, Yew SQ, Mohd Nawi A, Mohd Tohit N, et al
    Prevalence and risk factors of adverse work outcomes among manufacturing workers with Long COVID in Malaysia - A nationwide study.
    PLoS One. 2026;21:e0357125.
    PubMed         Abstract available
    
    
18. VALDES-LOPEZ JF, di Filippo D, Penagos S, Hernandez-Sarmiento LJ, et al
    SARS-CoV-2 infection induces functional impairment of vitamin D receptor signaling to drive interleukin 6-dependent hyperinflammation in mononuclear phagocytes.
    PLoS One. 2026;21:e0357030.
    PubMed         Abstract available
    
    
19. AMARSANAA J, Nguyen TXT, Khan MSR, Kadoya Y, et al
    The dynamics of loneliness: A longitudinal exploration of transitions in Japan across the COVID-19 period, 2020-2024.
    PLoS One. 2026;21:e0358269.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

20. LI L, Nguyen L, Qu H, Wu Q, et al
    Increased receptor binding and spike glycosylation, remodeled immune escape of surging SARS-CoV-2 subvariant BA.3.2.2/RE.2.2/Cicada.
    Proc Natl Acad Sci U S A. 2026;123:e2614163123.
    PubMed         Abstract available
    
    

    
    Vaccine

21. BUCKLIN R, Gauthreaux N, Faber E, Askelson N, et al
    Listening to micropolitan community leaders to support pandemic response efforts.
    Vaccine. 2025;60 Suppl 1:127255.
    PubMed         Abstract available
    
    
22. HOLLIDAY RC, Darkwa A, Brooks GA, Akintobi TH, et al
    Developing counter-narratives to address COVID-19 misinformation among 18-24 year olds in community and campus settings.
    Vaccine. 2025;60 Suppl 1:127135.
    PubMed         Abstract available
    
    
23. HEIMAN SL, Geiger N
    Overestimation of racial ingroup worry about the COVID-19 vaccine and medical racism.
    Vaccine. 2026;91:129046.
    PubMed         Abstract available
    
    
24. DUTTA S, Ngemera D, Jaillard P, Juneja S, et al
    Lessons learnt from one-year cold chain support for COVID-19 vaccination in 5 middle income countries of North Africa.
    Vaccine. 2026;91:128994.
    PubMed         Abstract available
    
    
25. CAMPBELL STATLER M, Bishop-Royse J, Sampson AT, Martin M, et al
    Heterogeneity among the vaccine hesitant: A secondary analysis of the national CEAL Common Survey data.
    Vaccine. 2026;91:129024.
    PubMed         Abstract available
    
    
26. KIM SJ, Kim HW, Son SE, Song JH, et al
    Wuhan-ancestral multi-antigen SARS-CoV-2 virus-like particles protect against the omicron sublineage JN.1 variant.
    Vaccine. 2026;91:129059.
    PubMed         Abstract available
    
    
27. FAHFOUHI Y, Fievez S, Cohen R, Levy C, et al
    A health-economic assessment of the impact of different RSVpreF maternal vaccine strategies to prevent RSV infections among young infants, in France: EPIPACT.
    Vaccine. 2026;91:129036.
    PubMed         Abstract available
    
    
28. BERIKOPOULOU MM, Tatsi EB, Siahanidou T, Michos A, et al
    Systematic review of the mutations in the active antigenic site O of the prefusion F protein of the Respiratory Syncytial Virus (RSV) following the implementation of monoclonal antibody prophylaxis.
    Vaccine. 2026;91:129069.
    PubMed         Abstract available
    
    
29. NUNES JPDS, Daher IP, Pires ADS, Yamamoto MM, et al
    Synergistic effect of AddaS03 and poly I:C adjuvants on antibody titers and Th1-biased T cell responses following RBD vaccination in BALB/c mice.
    Vaccine. 2026;91:129073.
    PubMed         Abstract available
    
    
30. MONOI A, Endo A, Kriznar M, Suzuki M, et al
    Comparing the potential impacts of seasonal immunisation against year-round immunisation to prevent RSV infant hospitalisations in Japan: A modelling study.
    Vaccine. 2026;91:129079.
    PubMed         Abstract available
    
    
31. SCHRARSTZHAUPT IN, Diaz-Quijano FA
    Effectiveness of COVID-19 vaccination schedules against severe COVID-19 in children aged 6 months to 4 years in Brazil: A population-based cohort study (2023-2024).
    Vaccine. 2026;91:129096.
    PubMed         Abstract available
    
    
32. ALAMI A, Lewis M, El-Chaar D, Walker M, et al
    Maternal vaccination with RSVpreF and risk of hypertensive disorders of pregnancy: a systematic review and meta-analysis.
    Vaccine. 2026;91:129070.
    PubMed         Abstract available
    
    
33. DENG L, Ye X, Chen X, Hu X, et al
    Secretory expression of tetrameric neuraminidase enhanced by signal peptide optimization elicits robust immunity against influenza infection in mice.
    Vaccine. 2026;92:129118.
    PubMed         Abstract available
    
    
34. SANBORN J, Robertson MM, Penrose K, Rane M, et al
    Gaps between willingness and uptake of influenza and COVID-19 vaccines during the 2025-26 respiratory virus season in a U.S. adult cohort.
    Vaccine. 2026;92:129126.
    PubMed         Abstract available
    
    
35. LU J, Ouyang Z, Huang F, Xie X, et al
    Real-world effectiveness of the influenza vaccine among school-aged children in Shenzhen, China, 2024-2025 season: A test-negative design study.
    Vaccine. 2026;92:129100.
    PubMed         Abstract available
    
    
36. THAKKAR V, Aryan Y, Gautam S, Joshi R, et al
    Influence of vaccine delivery route on immune imprinting in influenza vaccination.
    Vaccine. 2026;92:129109.
    PubMed         Abstract available
    
    
37. TORAIH EA, Hussein MH, Thomas SJ, Aiash H, et al
    Cardiac outcomes following SARS-CoV-2 infection versus BNT162b2 vaccination in adolescents and young adults: a cohort study of 4 million individuals.
    Vaccine. 2026;91:129001.
    PubMed         Abstract available
    
    
38. CABURNAY CA, Fu QJ, Carter T, Butler T, et al
    Identification of best outreach strategies and delivery modalities for population subgroups for COVID-19 vaccination.
    Vaccine. 2026;60 Suppl 1:128721.
    PubMed         Abstract available
    
    
39. CANACA G, Vicuna B, Hess JM, Cruz TH, et al
    From engagement to ownership: a qualitative study of a community-academic partnership to promote COVID-19 vaccine confidence among Latino/Hispanic communities in New Mexico.
    Vaccine. 2026;60 Suppl 1:128583.
    PubMed         Abstract available
    
    
40. STIEHL E, Negrete M, Flores G, Federmeyer L, et al
    Empowering communities during the COVID-19 pandemic: insights from trusted messengers about their work addressing COVID-19 vaccine hesitancy.
    Vaccine. 2026;60 Suppl 1:128559.
    PubMed         Abstract available
    
    
41. NUNO T, Soto S, Sepulveda R, Sierra LA, et al
    The Arizona prevention research center vaccine confidence network: A Mobile health unit intervention and survey results of barriers and facilitators to COVID-19 vaccination.
    Vaccine. 2025;60 Suppl 1:127970.
    PubMed         Abstract available
    
    
42. HARA-HUBBARD KK, Beaulieu A, Mendiola A, Gandhi P, et al
    Strategies for addressing COVID-19 vaccine equity with intermediaries, prevention research centers, and the vaccine confidence network.
    Vaccine. 2025;60 Suppl 1:127847.
    PubMed         Abstract available
    
    
43. CHUVILEVA YE, Kuiper NM, Ramakrishnan A, Goodman K, et al
    Weaving a public health network: Process and results from an evaluation of CDC's Prevention Research Centers Vaccine Confidence Network.
    Vaccine. 2025;60 Suppl 1:127636.
    PubMed         Abstract available
    
    
44. ALMUKHTAR S, McWhirter N, Mendiola A, Samuel S, et al
    Exploring lingering COVID-19 vaccine hesitancy in three diverse U.S. states: Alabama, Illinois, and Texas.
    Vaccine. 2025;60 Suppl 1:127664.
    PubMed         Abstract available
    
    
45. BEAULIEU A, LaMonaca K, Higginbottom J, Foster J, et al
    Utilizing the Program Impact Pathways framework for improving COVID-19 vaccine confidence and uptake: demonstrations of multi-sector collaboration from two geographies in Connecticut.
    Vaccine. 2025;60 Suppl 1:127623.
    PubMed         Abstract available
    
    
46. JEFFERS A, Kuiper NM, Ramakrishnan A, Swarna H, et al
    Building trust in community-academic partnerships: Strategies for enhancing vaccine confidence and demand - Lessons from Prevention Research Centers.
    Vaccine. 2025;60 Suppl 1:127624.
    PubMed         Abstract available
    
    
47. MCGEE RE, Barrett DA, Bednarczyk RA, Grant-Whitlock M, et al
    Engaging rural and non-Hispanic Black persons in conversations about the COVID-19 vaccine: a process evaluation of a natural helper intervention.
    Vaccine. 2025;60 Suppl 1:127587.
    PubMed         Abstract available
    
    
48. BORG A, Goulding M, Minkah P, Perrone D, et al
    Promotion of COVID-19 vaccination for youth and families in Worcester, Massachusetts: a Diffusion of Innovations approach.
    Vaccine. 2025;60 Suppl 1:127586.
    PubMed         Abstract available
    
    
49. SAVAS LS, Cuccaro P, Zhang K, Hernandez R, et al
    Factors influencing COVID-19 vaccine uptake among vulnerable communities in Texas: Perceptions of 2-1-1 helpline callers.
    Vaccine. 2025;60 Suppl 1:127554.
    PubMed         Abstract available
    
    
50. TOTZKAY D, Fraustino JD, Costello LM, Jarrett T, et al
    Building on West Virginia's innovative COVID-19 public health communication: associations between vaccination beliefs and vaccination messaging, partisanship, and social vulnerability.
    Vaccine. 2025;60 Suppl 1:127555.
    PubMed         Abstract available
    
    
51. O'CONNOR MH, Nyman AL, Ali S, Rothenberg R, et al
    Increasing vaccine uptake in a refugee resettlement community with high social vulnerability.
    Vaccine. 2025;60 Suppl 1:127552.
    PubMed         Abstract available
    
    
52. STIEHL E, Borg A, Cullen JP, Mendiola A, et al
    Engaging trusted messengers in public health response: Key strategies to building community trust among CDC'S prevention research center's vaccine confidence network.
    Vaccine. 2025;60 Suppl 1:127474.
    PubMed         Abstract available
    
    
53. HARA-HUBBARD KK, Flores Moreno MG, Sanchez M, Abdi N, et al
    The partnership for vaccine confidence: community-academic partnerships to promote COVID-19 vaccines to underserved urban and rural communities using the listen, plan, act, evaluate process.
    Vaccine. 2025;60 Suppl 1:127487.
    PubMed         Abstract available
    
    
54. MALLICK K, Handunge VL, Emmons KM, Blondet L, et al
    Engaging a community health ambassador model to promote COVID-19 vaccine in three Massachusetts communities.
    Vaccine. 2025;60 Suppl 1:127464.
    PubMed         Abstract available
    
    

    
    Virology

55. ISHIGAKI H, Otaki K, Kitagawa N, Ishida H, et al
    Pathogenicity of SARS-CoV-2 Omicron subvariants JN.1, EG.5.1, and BA.2.86.1 in immunologically naive cynomolgus macaques.
    Virology. 2026;624:111036.
    PubMed         Abstract available
    
    
56. LIU Z, Fan M, Zheng Y, Zeng Y, et al
    Transcriptome screening identifies circRNA-INSR as a novel host factor associated with avian influenza virus replication.
    Virology. 2026;625:111072.
    PubMed         Abstract available
    
    
57. MILLER AK, Heremia L, Waller SJ, Blanchard SL, et al
    Evaluating sampling strategies for the detection of avian influenza viruses in the environment.
    Virology. 2026;625:111069.
    PubMed         Abstract available
    
    

    
    Virus Res

58. ZHAO Y, Fan H
    Clinical impact of baloxavir-induced PA I38T/M substitutions in diverse influenza populations: a systematic review and meta-analysis.
    Virus Res. 2026;373:199797.
    PubMed         Abstract available

#Coronavirus Disease Research #References (AMEDEO, Sept. 5 '26)

 

BMJ

1. YANG YT
   Covid-19 vaccine study: scientific asylum should never have been necessary.
   BMJ. 2026;394:e100738.
   PubMed        
   
   

   
   Clin Infect Dis

2. TIPPETT A, Prasad PV, Begier E, Kim SS, et al
   Respiratory Syncytial Virus Hospitalizations in Adults >/=50 Years of Age and Those With Congestive Heart Failure or Chronic Obstructive Pulmonary Disease Exacerbations, 2018-2020.
   Clin Infect Dis. 2026;83:e416-e426.
   PubMed         Abstract available
   
   
3. GODWIN P, Shvachko V, Oppelt T, Wang CY, et al
   Retrospective Cohort Study Assessing Remdesivir Effectiveness in Hospitalized COVID-19 Patients With Renal or Hepatic Comorbidities.
   Clin Infect Dis. 2026 Sep 1:ciag534. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

4. THUNDAKATTIL AV, Prabhu R, Prabhu G, Mani M, et al
   Mixing versus matching booster vaccines: A longitudinal humoral immune kinetics against Omicron in a Malaysian cohort.
   Int J Infect Dis. 2026 Sep 4:109103. doi: 10.1016/j.ijid.2026.109103.
   PubMed         Abstract available
   
   
5. JIN M, Xin H, Zhang J, Huang X, et al
   Epidemiological Characteristics of Scarlet Fever in Liaoning Province, China: A Pre- and Post-Pandemic Comparison, 2005-2024.
   Int J Infect Dis. 2026 Sep 4:109081. doi: 10.1016/j.ijid.2026.109081.
   PubMed         Abstract available
   
   
6. KIM JS, Park JH, Kim J, Lee YC, et al
   Non-invasive aspergillosis following COVID-19 exacerbates the severity of SARS-CoV-2 infection.
   Int J Infect Dis. 2026 Sep 3:109095. doi: 10.1016/j.ijid.2026.109095.
   PubMed         Abstract available
   
   
7. XUE M, Zhou Z, Chao Y, Li J, et al
   Influenza A-Associated Pulmonary Aspergillosis in Critically Ill Patients in the Post-COVID-19 Era: A Multicenter Cohort Study from China.
   Int J Infect Dis. 2026 Aug 29:109089. doi: 10.1016/j.ijid.2026.109089.
   PubMed         Abstract available
   
   

   
   Intensive Care Med

8. MEZA-FUENTES G, Delgado I, Vial PA, Godoy-Faundez A, et al
   Temporal trends in critical care burden and outcomes of Andes virus-associated hantavirus cardiopulmonary syndrome: a national Chilean cohort.
   Intensive Care Med. 2026 Sep 2. doi: 10.1007/s00134-026-08599.
   PubMed         Abstract available
   
   

   
   J Infect

9. LOUBET P, Roubille F, Launay O, Fourati S, et al
   Cardiovascular outcomes and acute human metapneumovirus infection in adults: A systematic literature review.
   J Infect. 2026;93:106843.
   PubMed         Abstract available
   
   
10. WALKER JL, Ribeiro S, Litt D, Patel T, et al
    Antenatal pertussis vaccine effectiveness in England remains high post COVID-19.
    J Infect. 2026;93:106836.
    PubMed         Abstract available
    
    

    
    J Med Virol

11. FERRENA A, Schlamp F, Tuen M, Duerr R, et al
    Durable Interferon-Linked Blood Signatures During COVID-19 Convalescence.
    J Med Virol. 2026;98:e71133.
    PubMed         Abstract available
    
    

    
    J Virol

12. HU L, Tian R, Gao L, Xu N, et al
    PEDV envelope protein promotes viral replication by remodeling host iron homeostasis via the TRIM28-KLF15-FPN axis.
    J Virol. 2026 Sep 2:e0123926. doi: 10.1128/jvi.01239.
    PubMed         Abstract available
    
    
13. DARNLEY JA, Waller SJ, French RK, Parata R, et al
    Divergent coronaviruses discovered in the virome of lamprey with reddening syndrome.
    J Virol. 2026 Sep 2:e0064526. doi: 10.1128/jvi.00645.
    PubMed         Abstract available
    
    

    
    JAMA

14. LIPSON RA, Senerth E, Watson MA, Saini H, et al
    COVID-19 Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season.
    JAMA. 2026 Sep 2. doi: 10.1001/jama.2026.18191.
    PubMed         Abstract available
    
    
15. SENERTH E, Sheikholeslamian SM, Sivakumaran K, Watson MA, et al
    Influenza Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season.
    JAMA. 2026 Sep 2. doi: 10.1001/jama.2026.18126.
    PubMed         Abstract available
    
    
16. ROTEN L, Maurhofer J, Krisai P, Breitenstein A, et al
    Pulmonary Vein Isolation Using Pulsed Field Ablation With vs Without Posterior Wall Isolation in Patients With Symptomatic Persistent Atrial Fibrillation: The PIFPAF-PFA Randomized Clinical Trial.
    JAMA. 2026 Aug 29:e2617598. doi: 10.1001/jama.2026.17598.
    PubMed         Abstract available
    
    

    
    Lancet Infect Dis

17. BADEN LR, Shah NS, Liu STH, Cohen J, et al
    Nirmatrelvir-ritonavir targeting viral persistence in post-COVID-19 condition (long COVID) in the USA (RECOVER-VITAL): a randomised, double-blind, placebo-controlled, phase 2 trial.
    Lancet Infect Dis. 2026 Aug 31:S1473-3099(26)00406.
    PubMed         Abstract available
    
    

    
    Nature

18. MAKIN S
    When do infections lead to long COVID? Scientists close in on triggers and treatments for post-viral syndromes.
    Nature. 2026;657:26-28.
    PubMed 

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, Sept. 5 '26)

 

Antimicrob Agents Chemother

1. DE ANGELIS M, Gori Savellini G, Piselli E, Anichini G, et al
   Redox-sensitive factors as targets of thiol compounds to hinder SARS-CoV-2 replication and inflammatory response.
   Antimicrob Agents Chemother. 2026;70:e0051826.
   PubMed         Abstract available
   
   
2. JEENA N, Khan IA
   Targeting SARS-CoV-2 programmed -1 ribosomal frameshifting: structural dynamics and RNA-directed antiviral strategies.
   Antimicrob Agents Chemother. 2026;70:e0068726.
   PubMed         Abstract available
   
   
3. AVILA-PONCE DE LEON U, Esmaeili S, Owens K, Schiffer JT, et al
   Plasma concentrations of nirmatrelvir and molnupiravir required for inhibition of SARS-CoV-2 replication differ between rhesus macaques and humans.
   Antimicrob Agents Chemother. 2026 Aug 5:e0030726. doi: 10.1128/aac.00307.
   PubMed         Abstract available
   
   

   
   Antiviral Res

4. PU F, Guo Y, Pan X, Liu X, et al
   Dual-targeting engineered binding proteins block SARS-CoV-2 infection and complement activation.
   Antiviral Res. 2026;254:106515.
   PubMed         Abstract available
   
   
5. YURGELONIS I, Rai DK, Lee JT, Li Z, et al
   Antiviral activity of nirmatrelvir against contemporary SARS-CoV-2 variants.
   Antiviral Res. 2026;254:106517.
   PubMed         Abstract available
   
   

   
   Epidemiol Infect

6. NAQVI OH, Wendelboe AM, Beasley WH, Tyungu DL, et al
   Epidemiological characteristics of paediatric COVID-19 and influenza co-infections in the United States, 2020-2024 - CORRIGENDUM.
   Epidemiol Infect. 2026;154:e111.
   PubMed        
   
   

   
   J Infect Dis

7. ZHAO B, Zhang G, Wu J, Zhang W, et al
   Characterization of bronchiolitis and vaccine-induced enhanced respiratory disease in Syrian hamsters caused by respiratory syncytial virus infection.
   J Infect Dis. 2026 Mar 4:jiag136. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   J Virol

8. BHAVSAR D, Civljak A, Bonnettaz B, Arunkumar GA, et al
   Broadly reactive antibodies against influenza B virus hemagglutinin neutralize and protect through distinct structural mechanisms.
   J Virol. 2026 Sep 4:e0080226. doi: 10.1128/jvi.00802.
   PubMed         Abstract available
   
   
9. LIU D, Zhang Y, Zhang M, Guo R, et al
   A neuraminidase-targeting nanobody as a therapeutic candidate against influenza A and B viruses.
   J Virol. 2026 Aug 31:e0087426. doi: 10.1128/jvi.00874.
   PubMed         Abstract available
   
   

   
   JAMA

10. SENERTH E, Sheikholeslamian SM, Sivakumaran K, Watson MA, et al
    Influenza Vaccine Effectiveness and Safety for the 2026-2027 Respiratory Season.
    JAMA. 2026 Sep 2. doi: 10.1001/jama.2026.18126.
    PubMed         Abstract available
    
    

    
    Pediatrics

11. CHAN OW, Cheng YT, Liu YH, Chou IJ, et al
    Anakinra in Severe RSV-Associated Autoinflammatory Encephalopathy With Delayed ADEM-Like Changes.
    Pediatrics. 2026;158:e2026076364.
    PubMed         Abstract available
    
    
12. PAYNE AB, Battan-Wraith S, Reese SE, Hathaway CA, et al
    Effectiveness of RSV Prevention Strategies in US Infants: 2024-2025.
    Pediatrics. 2026 Aug 4:e2026076089. doi: 10.1542/peds.2026-076089.
    PubMed         Abstract available
    
    
13. MIN J, Tam V, Jacoby SF, McDonald CC, et al
    Community Firearm Violence, Youth Depression, and Suicide Risk in Philadelphia: 2017-2024.
    Pediatrics. 2026;158:e2025075438.
    PubMed         Abstract available
    
    

    
    PLoS Comput Biol

14. FREEDMAN AS, Nielsen BF, Saad-Roy CM, Grenfell BT, et al
    Economic factors promoting vaccine nationalism in the face of viral evolution.
    PLoS Comput Biol. 2026;22:e1014466.
    PubMed         Abstract available
    
    

    
    PLoS Med

15. ELIAS KM, Mitchell A, Stadler E, Schlub TE, et al
    Neutralising antibodies and protection from progression to severe COVID-19: A meta-analysis.
    PLoS Med. 2026;23:e1005230.
    PubMed         Abstract available
    
    

    
    PLoS One

16. ADAMCZYK G, Jablonski A, Nowakowski PT, Ptaszek RT, et al
    Theodicy perspective as an effect of the interpenetration of mental and religious issues during the COVID-19 pandemic in Poland.
    PLoS One. 2026;21:e0355379.
    PubMed         Abstract available
    
    
17. JUNGMANN SM, Garbe Huedo SF, Jacobs KAS, Pothorn NK, et al
    Mental load in women and mothers: Causes of distress, personality traits, and psychopathology.
    PLoS One. 2026;21:e0356255.
    PubMed         Abstract available
    
    
18. MOUNADI N, Nour H, El Kouali M, Samadi A, et al
    Repositioning antiviral phytoconstituents as broad-spectrum inhibitors of influenza A neuraminidase and human metapneumovirus fusion protein.
    PLoS One. 2026;21:e0348517.
    PubMed         Abstract available
    
    
19. HAWKES BA, Hollister J, Porter C, Lyski ZL, et al
    Age-specific humoral immune response to SARS-CoV-2: A comparative analysis of antibody levels in children and adults after vaccination with primary series or infection.
    PLoS One. 2026;21:e0356178.
    PubMed         Abstract available
    
    
20. AVSAR FN, Kilicaslan N, Sahutoglu T
    Comparative associations of Anakinra and Tocilizumab initiation with in-hospital mortality in severe COVID-19: A single-center sequential cohort study.
    PLoS One. 2026;21:e0357671.
    PubMed         Abstract available
    
    
21. SEEGERT N, Gaulin M, Chaiyakunapruk N, Navarro-Sanchez F, et al
    The impact of state- versus county-level mask mandates on economic activity during the COVID-19 pandemic.
    PLoS One. 2026;21:e0332243.
    PubMed         Abstract available
    
    
22. HARDY MJ, Williams CK, Ladman BS, Pitesky ME, et al
    Using high frequency GPS data to assess wintering goose proximity to commercial poultry facilities on the Delmarva peninsula for avian influenza risk management and surveillance.
    PLoS One. 2026;21:e0355415.
    PubMed         Abstract available
    
    
23. KOPP J, Spies Rodriguez DC, Kunzi L, Puhan MA, et al
    Physical activity in post-COVID-19 condition: A cross-sectional study.
    PLoS One. 2026;21:e0357465.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

24. KARADAKIC R, Keating NL, Barnett ML
    Interpreting vaccine-associated survival differences in immune checkpoint inhibitor therapy.
    Proc Natl Acad Sci U S A. 2026;123:e2621501123.
    PubMed         Abstract available
    
    

    
    Vaccine

25. MOHAMMED H, Andraweera P, Marshall HS
    A cohort study to assess the safety and coverage of COVID-19, influenza, and pertussis vaccine in Australian pregnant women.
    Vaccine. 2026;91:129081.
    PubMed         Abstract available
    
    
26. SHEN AK, Tupps C, Bino S, Chipoya M, et al
    Investments in seasonal influenza vaccination programs pack a punch for pandemic preparedness.
    Vaccine. 2026;92:129098.
    PubMed         Abstract available
    
    
27. TRAN S, McClymont E, Blitz S, Barrett J, et al
    Self-reported reactogenicity after COVID-19 vaccination with and without influenza vaccine coadministration during pregnancy in Canada.
    Vaccine. 2026;92:129122.
    PubMed         Abstract available
    
    
28. MARIA DA, Martins IM, Porto GPM, Villas-Boas IM, et al
    Safety, humoral and cellular immune responses to a pre-pandemic adjuvanted influenza A (H5N8) vaccine.
    Vaccine. 2026;92:129049.
    PubMed         Abstract available
    
    
29. ZHENG Y, Qiao B, Gao Z, Zhang X, et al
    Development of a subunit vaccine candidate (RBD-HA trimer) provides dual protection against multi-subtype avian influenza viruses and QX-type infectious bronchitis virus.
    Vaccine. 2026;92:129121.
    PubMed         Abstract available
    
    
30. KORNUTA CA, Zhou G, Kane KP, Vliagoftis H, et al
    Mucosal adjuvant activity of a PAR-2-activating peptide enhances lymph node immune cell recruitment and promotes immune cell activation in a prime-boost influenza vaccination model.
    Vaccine. 2026;92:129110.
    PubMed         Abstract available
    
    

    
    Virology

31. BROGAARD L, Laybourn HA, Kristensen C, Welner S, et al
    Site-specific microRNA responses in lungs of pigs depend on the host-adaptation of H1N1 influenza A virus.
    Virology. 2026;624:111053.
    PubMed         Abstract available
    
    
32. SEKINE W, Kamiki H, Ishida H, Matsugo H, et al
    HA1-T138A and HA1-Q226L substitutions in H3N2 canine influenza virus contribute to binding to human-type alpha2,6-linked sialic acid receptors.
    Virology. 2026;625:111071.
    PubMed         Abstract available
    
    
33. OLDENSAND F, Rafati N, Van Hoef V, Lundkvist A, et al
    Single-cell transcriptomic landscape of avian influenza H9N2 virus infection in human and chicken cells.
    Virology. 2026;625:111070.
    PubMed         Abstract available
    

#Coronavirus Disease Research #References (AMEDEO, August 29 '26)

 

Antiviral Res

1. PU F, Guo Y, Pan X, Liu X, et al
   Dual-targeting engineered binding proteins block SARS-CoV-2 infection and complement activation.
   Antiviral Res. 2026;254:106515.
   PubMed         Abstract available
   
   

   
   Clin Infect Dis

2. TRAUTNER BW, Cortes-Penfield NW, Gupta K, Hirsch EB, et al
   Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Selection of Antibiotic Therapy for Complicated UTI.
   Clin Infect Dis. 2025 Dec 19:ciaf460. doi: 10.1093.
   PubMed        
   
   
3. TRAUTNER BW, Cortes-Penfield NW, Gupta K, Hirsch EB, et al
   Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections: Timing of Intravenous to Oral Antibiotics Transition for Complicated UTI.
   Clin Infect Dis. 2025 Dec 19:ciaf461. doi: 10.1093.
   PubMed        
   
   

   
   Infect Control Hosp Epidemiol

4. PRAKASH-ASRANI R, Shioda K, Bower CW, Steinberg JP, et al
   Impact of hand hygiene on the detection of multidrug-resistant organisms and other pathogens of epidemiologic significance after implementation of an automated hand hygiene monitoring system.
   Infect Control Hosp Epidemiol. 2026 Aug 27:1-7. doi: 10.1017/ice.2026.10524.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

5. WAGATSUMA K, Song Z, Lam TTY, Kwok KO, et al
   Changes in respiratory virus seasonality across the COVID-19 pandemic: a multicentre comparative study in Leicester, Rotterdam, Hong Kong, and Christchurch.
   Int J Infect Dis. 2026 Aug 27:109080. doi: 10.1016/j.ijid.2026.109080.
   PubMed         Abstract available
   
   
6. RAGHUVAMSI PV, Loh SB, Bhattacharya P, Ho J, et al
   Investigating the effectiveness of multimodal data in forecasting SARS-COV-2 case surges.
   Int J Infect Dis. 2026 Aug 25:109062. doi: 10.1016/j.ijid.2026.109062.
   PubMed         Abstract available
   
   

   
   J Infect

7. SANDERSON ND, Dingle KE, Hopkins KMV, Vaughan A, et al
   Clinical validation of an optimised metagenomic nanopore sequencing method for detecting viral respiratory pathogens.
   J Infect. 2026 Aug 22:106839. doi: 10.1016/j.jinf.2026.106839.
   PubMed         Abstract available
   
   

   
   J Med Virol

8. LI J, Song W, Li J, Peng R, et al
   Enhanced Immunogenicity and Cross-Neutralizing Activity of a Trivalent Adenoviral Vector-Based SARS-CoV-2 Vaccine in Mice.
   J Med Virol. 2026;98:e71119.
   PubMed         Abstract available
   
   

   
   J Virol

9. LIU G, Chen J, Wu F, Wei P, et al
   Nanobodies targeting SARS-CoV-2 papain-like protease exert dual antiviral and anti-inflammatory effects.
   J Virol. 2026 Aug 28:e0059926. doi: 10.1128/jvi.00599.
   PubMed         Abstract available
   
   
10. STADLER E, Mordant F, Gartner M, Docken SS, et al
    Reconciliation of titer differences between SARS-CoV-2 neutralizing antibody assays.
    J Virol. 2026 Aug 27:e0082326. doi: 10.1128/jvi.00823.
    PubMed         Abstract available
    
    
11. DE BEIJER NL, Limpens RWAL, Barcena M, Snijder EJ, et al
    Conserved structural features of RNA export pores spanning the double membrane of arterivirus and coronavirus replication organelles.
    J Virol. 2026 Aug 26:e0085926. doi: 10.1128/jvi.00859.
    PubMed         Abstract available
    
    
12. KUMAR S, Lai L, Ellis ML, Patel A, et al
    Immunological imprinting shapes the cross-reactive antibody responses to the KP.2 and LP.8.1 vaccine doses.
    J Virol. 2026 Aug 26:e0074926. doi: 10.1128/jvi.00749.
    PubMed         Abstract available
    
    

    
    JAMA

13. CHUNG TH, Raj SR
    Postural Orthostatic Tachycardia Syndrome (POTS): A Review.
    JAMA. 2026 Aug 24. doi: 10.1001/jama.2026.14809.
    PubMed         Abstract available
    

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, August 29 '26)

 

BMC Pediatr

1. ROHDE G, Haraldstad K, Helseth S, Hagen M, et al
   Health-related quality of life in parents of adolescents in 2019, 2021 and 2023.
   BMC Pediatr. 2026;26:783.
   PubMed         Abstract available
   
   
2. ZHU L, Zeng L, Zhang M, Chen X, et al
   Comparison of human metapneumovirus and respiratory syncytial virus in children with acute lower respiratory infections in Wenzhou, China from 2021 to 2022: a retrospective study.
   BMC Pediatr. 2026;26:774.
   PubMed         Abstract available
   
   

   
   J Immunol

3. DICK JK, Krishna VD, Hicks D, Sangala JA, et al
   ACE2 decoy Fc-fusions and bispecific killer engagers require Fc engagement for in vivo efficacy against SARS-CoV-2.
   J Immunol. 2026;215:vkag235.
   PubMed         Abstract available
   
   

   
   J Virol

4. ALYMOVA IV, Mekonnen B, Wang D, Kamal RP, et al
   N-linked glycosylation sites with low occupancy support sustained circulation of the A(H3N2) influenza A virus in the human population.
   J Virol. 2026 Aug 28:e0066226. doi: 10.1128/jvi.00662.
   PubMed         Abstract available
   
   
5. BARRE RS, Nath H, Nogales A, Abdelwhab EM, et al
   NS-segment-based reporter influenza A viruses: engineering strategy, applications, and limitations.
   J Virol. 2026 Aug 26:e0109926. doi: 10.1128/jvi.01099.
   PubMed         Abstract available
   
   

   
   PLoS Comput Biol

6. KENNEDY J, Ferguson W, Jones O, Riley S, et al
   Evaluation of short-term multi-target respiratory forecasts over winter 2024-25 in England using sub-ensemble contribution analyses.
   PLoS Comput Biol. 2026;22:e1014644.
   PubMed         Abstract available
   
   
7. OSTHUS D, Murph AC, Goldberg EE, Beesley LJ, et al
   Leveraging synthetic and genetic data to improve epidemic forecasting.
   PLoS Comput Biol. 2026;22:e1014630.
   PubMed         Abstract available
   
   

   
   PLoS One

8. HO QM, Duong BT, Nguyen LNT, Susilawati TN, et al
   ICU admission and mortality in adult patients with influenza A(H1N1)pdm09-related pneumonia in Vietnam since the 2009 H1N1 pandemic: A 10-year cohort study.
   PLoS One. 2026;21:e0348450.
   PubMed         Abstract available
   
   
9. NASH RK, Bhatia S, Wardle J, Cori A, et al
   Forecasting COVID-19 cases in US states using reconstructed incidence data.
   PLoS One. 2026;21:e0353983.
   PubMed         Abstract available
   
   
10. ARTEMCHUK O, Chakhunashvili G, Finci I, Rojas M, et al
    Factors associated with influenza vaccine uptake among healthcare workers in Georgia, 2021-2024.
    PLoS One. 2026;21:e0356495.
    PubMed         Abstract available
    
    
11. MENDOZA-VELAZQUEZ A, Lara-Arevalo J, Mendoza-Martinez L, Drewnowski A, et al
    Rising food prices and widening nutrition gaps in Mexico: The cost of nutrient-dense and ultra-processed foods before, during, and after COVID-19.
    PLoS One. 2026;21:e0355198.
    PubMed         Abstract available
    
    
12. OVERBOSCH FW, Waltz CNM, Cesuroglu T, Blokland B, et al
    Exploring integrated advice and avian influenza knowledge gaps by using a Highly Pathogenic Avian Influenza outbreak simulation.
    PLoS One. 2026;21:e0354920.
    PubMed         Abstract available
    
    
13. SHARMA S, Elhassan H, Anderson KK, Heisel MJ, et al
    Changes in mental health outcomes of middle-aged and older adults during the COVID-19 pandemic: A scoping review.
    PLoS One. 2026;21:e0342140.
    PubMed         Abstract available
    
    
14. EKHOLUENETALE M
    Decomposing socioeconomic inequalities in COVID-19 vaccination uptake among Nigerian women of reproductive age: A further analysis of population-based data.
    PLoS One. 2026;21:e0357171.
    PubMed         Abstract available
    
    
15. PUEBLA G, Ferrer-Urbina R, Perez-Zapata D, Alarcon-Castillo K, et al
    Cognitive load and individual differences as drivers of health-related misinformation: A signal detection approach.
    PLoS One. 2026;21:e0356642.
    PubMed         Abstract available
    
    

    
    Proc Natl Acad Sci U S A

16. RIUMINA ED, Alekseeva EI, Klink GV, Feigin S, et al
    HLA class I escape drives the evolution of SARS-CoV-2 in human populations.
    Proc Natl Acad Sci U S A. 2026;123:e2619192123.
    PubMed         Abstract available
    
    
17. LIU Q, Chen P, He C, Qiu Z, et al
    SESN1 is a negative regulator of MAVS and dynamically expressed during RNA viral infection.
    Proc Natl Acad Sci U S A. 2026;123:e2621443123.
    PubMed         Abstract available
    
    
18. MONTGOMERIE I, McKenzie RE, Palmer OR, Mason NC, et al
    Engineering antigenic breadth against SARS-CoV-2 by pairing divergent RBDs within a single mRNA immunogen.
    Proc Natl Acad Sci U S A. 2026;123:e2602574123.
    PubMed         Abstract available
    
    

    
    Vaccine

19. KOONIN LM, Velez SD, Bresee JS
    Expanding adult immunization in low- and middle-income countries through pharmacist-provided vaccination.
    Vaccine. 2026;90:129004.
    PubMed         Abstract available
    
    
20. KAZENZA B, Masokolo B, Mbunga B, Egbende L, et al
    Why COVID-19 vaccination struggled in the Democratic Republic of Congo: a qualitative study exploring organizational and sociocultural barriers, 2025.
    Vaccine. 2026;90:129033.
    PubMed         Abstract available
    
    
21. HUIBERTS AJ, Eggink D, de Gier B, Karens T, et al
    Effectiveness of Omicron JN.1 vaccination against infection with JN.1-derived SARS-CoV-2 subvariants in a prospective cohort study in the Netherlands.
    Vaccine. 2026;90:129030.
    PubMed         Abstract available
    
    
22. HUTTON DW, Prosser LA, Ortega-Sanchez IR, Leidner AJ, et al
    Evaluating the cost-effectiveness of respiratory syncytial virus vaccination among risk-stratified older adults.
    Vaccine. 2026;90:129023.
    PubMed         Abstract available
    
    
23. PORTILHO AI, Andreata-Santos R, Duarte-Barbosa M, Chaves APC, et al
    Functional neutralizing and bactericidal antibody responses induced by dual-target immunization with SARS-CoV-2 RBD and Neisseria meningitidis antigens in mice.
    Vaccine. 2026;90:129011.
    PubMed         Abstract available
    
    
24. AHI T, Andersen KM, Mateus JS, Yu T, et al
    2024-2025 BNT162b2 KP.2 COVID-19 full season vaccine effectiveness from vaccine registries linked to administrative claims in two states: A cohort study in non-immunocompromised adults.
    Vaccine. 2026;90:129009.
    PubMed         Abstract available
    
    
25. LIU X, Cloughesy JN, Yu T, Ferranna M, et al
    Uptake of the RSVpreF vaccine during pregnancy: associations with socioeconomic status, prenatal care utilization, and maternal risk factors.
    Vaccine. 2026;90:129003.
    PubMed         Abstract available
    
    
26. KAZI F, Shapland CY, Spiga F, Villanueva G, et al
    Implications for future pandemics from a living systematic review and critical evaluation of observational studies of the effectiveness of COVID-19 vaccination against the Omicron variant.
    Vaccine. 2026;90:128993.
    PubMed         Abstract available
    
    
27. HUIBERTS AJ, Smits MMJ, Hoeve CE, de Melker HE, et al
    Association between post-vaccination adverse events and subsequent COVID-19 booster uptake in the Netherlands.
    Vaccine. 2026;90:129043.
    PubMed         Abstract available
    
    
28. GENSOROWSKY D, Surmann B, Meyer AC, Poshtiban A, et al
    Corrigendum to "Outpatient care intensity and influenza vaccination: evidence from Germany" [Vaccine 70 (2026) 128038].
    Vaccine. 2026;90:129062.
    PubMed        
    
    
29. BOTT L, Liu J, Challenger A, Powell E, et al
    Myth-busting influenza and fear of adverse reactions in healthcare workers: two experimental studies on vaccination intentions.
    Vaccine. 2026;91:129086.
    PubMed         Abstract available

#Coronavirus Disease Research #References (AMEDEO, August 22 '26)

 

Antiviral Res

1. YURGELONIS I, Rai DK, Lee JT, Li Z, et al
   Antiviral activity of nirmatrelvir against contemporary SARS-CoV-2 variants.
   Antiviral Res. 2026;254:106517.
   PubMed         Abstract available
   
   
2. MALUNE P, Kullik G, Jia X, Bandowski G, et al
   gamma-Monoalkyl triphosphate analogues of acyclic nucleoside phosphonates inhibit SARS-CoV-2 replication in vitro by inducing dissociation of the minimal replication-transcription complex.
   Antiviral Res. 2026;254:106514.
   PubMed         Abstract available
   
   
3. ZOU J, Su L, Lu J, Jing H, et al
   Oligomerized receptor binding domain blocks pan-sarbecovirus infection via enhanced avidity to host receptor.
   Antiviral Res. 2026;254:106516.
   PubMed         Abstract available
   
   

   
   BMJ

4. O'DOWD A
   Covid-19: 40% of affected healthcare workers had long covid, and a quarter still had symptoms after a year.
   BMJ. 2026;394:e100628.
   PubMed        
   
   

   
   Clin Infect Dis

5. RUBIS AB, Youngkin E, Firmender P, Argueta G, et al
   Updated Assessment of the Impact of the Modified Council of State and Territorial Epidemiologists Case Definition for Pertussis on Reported Pertussis.
   Clin Infect Dis. 2026 Aug 22:ciag515. doi: 10.1093.
   PubMed         Abstract available
   
   

   
   Int J Infect Dis

6. PINTO TF, Santoro A, de Oliveira ALG, Tavares TS, et al
   Risk of Post-acute Symptoms and Conditions After SARS-CoV-2 Compared to Other Respiratory Viral Infections: A Systematic Review and Meta-Analysis.
   Int J Infect Dis. 2026 Aug 21:109056. doi: 10.1016/j.ijid.2026.109056.
   PubMed         Abstract available
   
   
7. KHAN SMA, Irfan S, Ashraf J, Ghayas H, et al
   Molecularepidemiology and antimicrobial resistance determinants of Corynebacterium diphtheriae causing infections in Karachi, Pakistan, 2023-2024.
   Int J Infect Dis. 2026 Aug 20:109058. doi: 10.1016/j.ijid.2026.109058.
   PubMed         Abstract available
   
   
8. ANZAI A, Nishiura H
   Post-hoc evaluation of travel restrictions during the COVID-19 pandemic in Japan, 2020-2022.
   Int J Infect Dis. 2026 Aug 17:109068. doi: 10.1016/j.ijid.2026.109068.
   PubMed         Abstract available
   
   
9. RAHMOUN MA, Sabate-Elabbadi A, Brun-Buisson C, Watier L, et al
   Impact of the COVID-19 pandemic on the association between sepsis etiology and mortality among ICU patients in France.
   Int J Infect Dis. 2026 Aug 16:109060. doi: 10.1016/j.ijid.2026.109060.
   PubMed         Abstract available
   
   
10. LEAO V, Assad Z, Valtuille Z, Ouldali N, et al
    Shifts in unidentified-pathogen acute hematogenous osteomyelitis incidence after non-pharmaceutical interventions highlight the role of seasonal viruses: an interrupted time-series analysis.
    Int J Infect Dis. 2026 Aug 16:109054. doi: 10.1016/j.ijid.2026.109054.
    PubMed         Abstract available
    
    
11. PENG B, Allen-Benson D, Talebi Y, Ghosh S, et al
    Temporal, Demographic, and Geographic Patterns of Long COVID Incidence in Relation to SARS-CoV-2 Variant Emergence: Insights from the Texas All-Payer Claims Database (TX-APCD).
    Int J Infect Dis. 2026 Aug 16:109051. doi: 10.1016/j.ijid.2026.109051.
    PubMed         Abstract available
    
    
12. AZHAR EI, Alqahtani M, Assiri AM, Al-Abri SS, et al
    MERS-CoV in the Middle East and Africa: from surveillance gaps in humans and dromedary camels to One Health frameworks for spillover, prevention, research and response preparedness.
    Int J Infect Dis. 2026 Aug 15:109046. doi: 10.1016/j.ijid.2026.109046.
    PubMed         Abstract available
    
    

    
    J Med Virol

13. FERRO V, Cozzolino C, Olita C, Severini F, et al
    Viral Landscape, Clinical Impact, and Management Trends in Hospitalized Children for Viral-Associated Lower Respiratory Tract Diseases: A Comparative Analysis of Two Post-Pandemic Seasons in Rome, Italy.
    J Med Virol. 2026;98:e71103.
    PubMed         Abstract available
    
    
14. HUANG Z, Liu W, Zhang N, Guo H, et al
    Respiratory Virus Immunological Dynamics in the Post-Pandemic Era of Southeastern China: A Retrospective Serological Investigation.
    J Med Virol. 2026;98:e71112.
    PubMed         Abstract available
    
    

    
    J Virol

15. ZHANG Y, Fujita S, Kajihara M, Changula K, et al
    Novel African Rhinolophus bat ACE2 sequences reveal the determinants of Afro-Eurasian sarbecovirus entry.
    J Virol. 2026 Aug 21:e0054026. doi: 10.1128/jvi.00540.
    PubMed         Abstract available
    
    
16. ZHENG Y, Luo D, Tian Q, Zhang M, et al
    TPPS4 inhibits PEDV by stabilizing viral RNA G-quadruplex and promoting ER stress: a transfer-learning-driven discovery.
    J Virol. 2026;100:e0077426.
    PubMed         Abstract available
    
    

    
    Lancet Infect Dis

17. BASNYAT B, Adhikari S, Shrestha P, Budhathoki S, et al
    Azithromycin with or without cefixime for suspected or culture-confirmed uncomplicated typhoid fever in Nepal, Bangladesh, and Pakistan (ACT-South Asia): a double-blind, parallel-group, randomised, placebo-controlled, phase 4 trial.
    Lancet Infect Dis. 2026 Aug 20:S1473-3099(26)00358.
    PubMed         Abstract available

#Influenza and Other Respiratory Viruses Research #References (AMEDEO, August 22 '26)

 

BMC Pediatr

1. XIA Z, Zhang H, Xu S, Lin X, et al
   Changes in pediatric pneumonia incidence and pathogen spectrum before, during, and after the COVID-19 pandemic: an eight-year inpatient data analysis from a tertiary hospital in Fujian, China.
   BMC Pediatr. 2026;26:766.
   PubMed         Abstract available
   
   

   
   Cell

2. LI L, Yan XL, Wang HY, Zhou HY, et al
   Viral protease-initiated lytic cell death as a universal antiviral mRNA therapy.
   Cell. 2026;189:5396-5410.
   PubMed         Abstract available
   
   

   
   J Gen Virol

3. SHIM K, Choi JH, Hwang EH, Kim G, et al
   Dose-dependent effects of recombinant spike protein-based vaccination on SARS-CoV-2 evolutionary dynamics and the emergence of variants in hamster models.
   J Gen Virol. 2026;107:002314.
   PubMed         Abstract available
   
   
4. GRANSTAD S, Tonnessen R, Ytrehus B, Descamps S, et al
   Multiple introductions of highly pathogenic avian influenza viruses into the High Arctic: Svalbard and Jan Mayen, 2022-2025.
   J Gen Virol. 2026;107:002305.
   PubMed         Abstract available
   
   

   
   J Virol

5. XU J, Chan H-w, Yang R, Wu X-R, et al
   Nicotine and cotinine enhance SARS-CoV-2 entry through distinct but complementary mechanisms in human respiratory epithelial cells.
   J Virol. 2026 Jul 31:e0097126. doi: 10.1128/jvi.00971.
   PubMed         Abstract available
   
   
6. HE L, Su Y-WN, Zhang F, Moustafa IM, et al
   Recovery of proofreading-impaired SARS-CoV-2 reveals a mutator phenotype and an ExoN activity threshold for viability.
   J Virol. 2026 Jul 29:e0080926. doi: 10.1128/jvi.00809.
   PubMed         Abstract available
   
   
7. BEETON K, Case JB
   Respiratory mucosal vaccines for emerging viruses: promise and challenges.
   J Virol. 2026 Jul 23:e0174825. doi: 10.1128/jvi.01748.
   PubMed         Abstract available
   
   
8. ZHOU R, Yue M, Shen Q, Liu N, et al
   Glucagon-like peptide-1 receptor agonist prevents pulmonary fibrosis following acute COVID-19 infection associated with type 2 diabetes.
   J Virol. 2026 Jul 9:e0040126. doi: 10.1128/jvi.00401.
   PubMed         Abstract available
   
   
9. LAMICHHANE P, Yang L, Santos C, Park H-S, et al
   Live human metapneumovirus vaccine candidates attenuated by temperature sensitivity mutations from human respiratory syncytial virus.
   J Virol. 2026 Jul 6:e0069226. doi: 10.1128/jvi.00692.
   PubMed         Abstract available
   
   

   
   Pediatrics

10. HUANG YN, Chang CJ, Dai YL, Kung YH, et al
    Early Antiviral Therapy in Pediatric Outpatients and Risk of Influenza-Related Hospitalization.
    Pediatrics. 2026 Aug 17:e2025075020. doi: 10.1542/peds.2025-075020.
    PubMed         Abstract available
    
    
11. ANTOON JW, Edwards KM
    Why Not Antivirals? Reconsidering Influenza Treatment in Children.
    Pediatrics. 2026 Aug 17:e2026076953. doi: 10.1542/peds.2026-076953.
    PubMed        
    
    

    
    PLoS Comput Biol

12. KRAMER SC, Pirikahu S, Kussmaul C, Opatowski L, et al
    The limitations of non-mechanistic methods for characterizing pathogen-pathogen interactions: A simulation study.
    PLoS Comput Biol. 2026;22:e1013859.
    PubMed         Abstract available
    
    
13. DIMITRIOU PA, D'Alessandro M, Chang BL, Silvestros V, et al
    Non-Markovian dynamics and effective reproduction number in COVID-19: Evidence from Cyprus contact tracing data.
    PLoS Comput Biol. 2026;22:e1014578.
    PubMed         Abstract available
    
    

    
    PLoS Med

14. KAMTCHUM-TATUENE J, Farrell J, Nolan J, Lessels S, et al
    Time trends in stroke incidence and modifiable risk factor prevalence in England (2018-2024): A record linkage population-based study.
    PLoS Med. 2026;23:e1004999.
    PubMed         Abstract available
    
    

    
    PLoS One

15. DI CHIARA C, Piche-Renaud PP, Rigamonti V, Cantarutti A, et al
    Pediatricians' attitudes and knowledge of RSV immunization products: A multi-country cross-sectional survey.
    PLoS One. 2026;21:e0356233.
    PubMed         Abstract available
    
    
16. APONTE-HAO S, Luu H, Martins KJB, Randall JR, et al
    Factors associated with severe COVID-19 outcomes among adults with at least a primary vaccination schedule: A retrospective cohort study from Alberta, Canada.
    PLoS One. 2026;21:e0354822.
    PubMed         Abstract available
    
    
17. SHANKER N, Reckling S, Snyder NL, Enright D, et al
    Addressing gaps in surveillance: Use of emergency department accessibility and social vulnerability to identify potential wastewater surveillance sites in North Carolina.
    PLoS One. 2026;21:e0346668.
    PubMed         Abstract available
    
    
18. KOSINSKA-SELBI B, Kowalczyk J, Pierscinska J, Weleszczuk J, et al
    Comprehensive and innovative post-market surveillance system for atypical respiratory pathogens detecting qPCR panel.
    PLoS One. 2026;21:e0349967.
    PubMed         Abstract available
    
    
19. D'SOUZA-RUSHTON GC, Seshu U, Blumberger L, Mazhar L, et al
    The CDC's management and COVID-19 vaccine recommendations during the COVID-19 pandemic: A healthcare worker's perspective.
    PLoS One. 2026;21:e0354686.
    PubMed         Abstract available
    
    
20. MOSSOP B, Choudhury S
    Regime-aware causal Bayesian forecasting for non-stationary time series.
    PLoS One. 2026;21:e0356474.
    PubMed         Abstract available
    
    
21. HUNG LF, Guo PX, Hou CY, Kuo YH, et al
    Changes in multidrug-resistant Enterobacteriaceae features among patients in the emergency room during the COVID-19 Omicron variant pandemic.
    PLoS One. 2026;21:e0355725.
    PubMed         Abstract available
    
    
22. 
    Correction: The interaction of RNA G-quadruplexes from the influenza A virus vRNA with TMPyP4 and BRACO-19 ligands.
    PLoS One. 2026;21:e0356274.
    PubMed         Abstract available
    
    

    
    Vaccine

23. TANI N, Sato T, Goto T, Harada Y, et al
    Longitudinal changes in the antibody responses and adverse reactions across successive SARS-CoV-2 mRNA vaccinations from the primary series to the JN.1-adapted booster in hospital employees: A 4-year prospective cohort study.
    Vaccine. 2026;89:128887.
    PubMed         Abstract available
    
    
24. EZEJA L, Ezeala OM, Westrick SC, Qian J, et al
    Adverse events and vaccine administration errors following RSV vaccination: Findings from the United States VAERS database, 2023-2025.
    Vaccine. 2026;89:128896.
    PubMed         Abstract available
    
    
25. LIU STH, Gonzalez-Dominguez I, Martinez-Perez A, Bozkus CC, et al
    Phase 1 trial of intranasal NDV-HXP-S in previously vaccinated adults.
    Vaccine. 2026;89:128870.
    PubMed         Abstract available
    
    
26. KAUTZ A, Yang DH, Chickery S, Irving SA, et al
    Influence of correlated vaccination behaviors on estimates of COVID-19 vaccine effectiveness in older adults - VISION network, October 2023 - March 2024.
    Vaccine. 2026;89:128891.
    PubMed         Abstract available
    
    
27. BROWN J, Brennan H, Levine CB, Gwynn L, et al
    A historical overview of the anti-vaccine movement and its public health implications.
    Vaccine. 2026;89:128903.
    PubMed         Abstract available
    
    
28. DEPICKERE S, Pannus P, Houben S, Charles A, et al
    Safety and immunogenicity of a reduced, homologous booster dose of the BNT162b2 mRNA COVID-19 vaccine: a single blind, randomized, non-inferiority follow-up trial.
    Vaccine. 2026;89:128897.
    PubMed         Abstract available
    
    
29. KANDULU CC, Fleming A, O'Mahony A, McHugh S, et al
    Barriers and facilitators to COVID-19 vaccination programme implementation in Ireland: a qualitative study of implementation stakeholders using CFIR.
    Vaccine. 2026;89:128909.
    PubMed         Abstract available
    
    
30. WILLIAMS J, Degeling C, Donovan L, Wiley K, et al
    Australians' attitudes to mRNA vaccination in humans and animals: A cross-sectional survey.
    Vaccine. 2026;89:128907.
    PubMed         Abstract available
    
    
31. SANDERS JG, Kroese F, Mehra S, Stok M, et al
    Switching the default: a formative evaluation of pre-booked appointments on COVID-19 vaccination uptake and effects on intended uptake.
    Vaccine. 2026;89:128967.
    PubMed         Abstract available
    
    
32. MAZIBUKO L, Hoor D, Nxumalo V, Nxumalo S, et al
    The association of individual, interpersonal and social support factors with willingness to vaccinate against COVID-19 in rural South Africa.
    Vaccine. 2026;89:128998.
    PubMed         Abstract available
    
    
33. AUGUSTO LV, de Araujo LP, Silva EN, Gutierres JM, et al
    Intersection of vaccination, health literacy, education, and communication in South America: A scientometric mapping.
    Vaccine. 2026;89:128986.
    PubMed         Abstract available
    
    
34. SUZUKI Y, Arita T, Shirakura M, Kishida N, et al
    A novel candidate vaccine virus derived from Japan's first mammalian case of clade 2.3.4.4b A/H5N1 highly pathogenic avian influenza virus.
    Vaccine. 2026;91:129048.
    PubMed         Abstract available
    
    
35. DHANDA S, Morris DE, Morton K, Hazell L, et al
    Enhanced passive safety surveillance (EPSS) of a seasonal intranasal influenza vaccine (Fluenz(R) Tetra) in children in England: methodology, results and lessons learned from eight influenza seasons (2015/2016 to 2022/2023).
    Vaccine. 2026;91:129007.
    PubMed         Abstract available
    
    
36. HERMANN E, Krammer F
    The return of H1N1: Reemergence of the influenza virus A subtype H1N1 in 1977.
    Vaccine. 2026;91:128963.
    PubMed         Abstract available